🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

RecruitingPhase 2Ages 16 Years - anyAllAC Camargo Cancer Center
NCT06472388 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Everolimus is approved in many countries to treat patients with advanced/metastatic well-differentiated neuroendocrine tumors (NET), providing median progression-free survival times of approximately 12 months across different types of NET. However, it is can cause severe adverse effects. Phase I trial demonstrated that a dose of 5mg/day/week was sufficient to inhibit cell proliferation by blocking the mTOR pathway. This is a randomized, open-label, phase II near-equivalence clinical trial of oral everolimus 5 mg vs 10 mg oral/daily and continuously in patients with Grade 1 or Grade 2 metastatic NET, with tumor progression or intolerance to at least one line of treatment and with radiological disease progression within 6 months.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histological confirmation of well-differentiated Grade 1/Grade 2 NET from gastrointestinal, pancreatic, pulmonary or unknown primary sites. * Metastatic or locally advanced and unresectable disease, measurable by images * Disease progression by RECIST 1.1 in the last 6 months assessed by local investigators * At least one previous line of systemic treatment (suspended for more than 3 weeks). * Eastern Cooperative Oncology Group (ECOG) 0-2 o Good organ function: * Hemoglobin \> 8 g/dL * Neutrophils ≥ 1,500/mm³ * Platelets \> 90,000/mm³ * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN \[upper limit of normal\] or ≤ 5 x ULN for patients with liver metastases * Bilirubin ≤ 1.5 x ULN, creatinine \< 1.5 mg/dL Exclusion Criteria: * Aggressive disease requiring cytotoxic therapy * Severe/uncontrolled comorbid conditions that deem participant unfit for everolimus therapy, as per investigators' judgement. * MiNEN
💊

What it tests

  • Everolimus 5 MG
📍

Where

2 sites
AC Camargo Cancer Center
São Paulo, Brazil
AC Camargo Cancer Center
São Paulo, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy